Baltijos bioinovacijos - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 0 | - | - | - | 681,047 | 1,322,079 | 1,237,613 | 1,169,776 |
| Profit before tax | -1 | - | - | - | 28,646 | 104,942 | 25,782 | 46,133 |
| Net profit | -1 | 0 | 0 | 0 | 24,344 | 89,081 | 22,026 | 37,911 |
| Equity | 0 | 2,896 | 2,896 | 2,896 | 27,240 | 116,321 | 138,347 | 176,258 |
| Liabilities | 0 | 0 | 0 | 0 | 73,902 | 114,387 | 159,632 | 87,838 |
| Non-current assets | 0 | 0 | 0 | 0 | 14,584 | 91,864 | 163,843 | 126,490 |
| Current assets | 0 | 2,896 | 2,896 | 2,896 | 86,558 | 138,844 | 130,940 | 131,107 |
| Total assets | 0 | 2,896 | 2,896 | 2,896 | 101,142 | 230,708 | 294,783 | 257,597 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 81,048 | 72,612 | 91,131 |
| Social insurance contributions | - | - | - | - | - | 28,060 | 31,701 | 30,964 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | - | - | - | +94.1% | -6.4% | -5.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | 0.0% | 0.0% | 0.0% | 24.1% | 38.6% | 7.5% | 14.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 0.0% | 0.0% | 0.0% | 89.4% | 76.6% | 15.9% | 21.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | 3.6% | 6.7% | 1.8% | 3.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | 4.2% | 7.9% | 2.1% | 3.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 2.7 | 1.0 | 1.2 | 0.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | 133,249 | 178,257 | 144,188 | 157,722 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Baltijos bioinovacijos - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-05-02 | 2023-05-07 | 4.48 |
| 2023-04-26 | 2023-04-28 | 4.48 |
| 2023-04-18 | 2023-04-25 | 4.41 |
| 2023-03-20 | 2023-04-06 | 4.41 |
| 2023-02-17 | 2023-03-12 | 10.01 |
| 2022-11-21 | 2022-11-21 | 1589.83 |
| 2022-11-17 | 2022-11-18 | 1589.83 |
| 2022-08-23 | 2022-08-31 | 222.53 |
Baltijos bioinovacijos - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-03-10 | 2025-03-17 | 3.7 |
| 2025-02-28 | 2025-03-09 | 6.33 |
| 2025-02-25 | 2025-02-27 | 2.84 |
| 2025-02-20 | 2025-02-24 | 110.74 |
| 2025-02-06 | 2025-02-07 | 0.21 |
| 2025-01-10 | 2025-01-25 | 13.64 |
| 2025-01-08 | 2025-01-09 | 13.64 |
| 2025-01-10 | 2025-01-09 | 143.36 |
| 2025-01-01 | 2025-01-07 | 4580.89 |
| 2024-12-31 | 2024-12-31 | 4579.65 |
| 2024-12-30 | 2024-12-30 | 4575.93 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Baltijos bioinovacijos, UAB (code 302514537) is a Private Limited Liability Company engaged in engineering design and construction activities. In 2025, the company generated revenue of €1.17M and net profit of €37.9K, with a profit margin of 3.2%. Revenue has declined gradually from €1.32M in 2023 to €1.24M in 2024 and €1.17M in 2025, while profitability weakened in 2024 before improving again in 2025. Net profit moved from €89.1K in 2023 to €22.0K in 2024 and then rose to €37.9K in 2025. The balance sheet remained moderately leveraged, with total assets of €257.6K, equity of €176.3K and liabilities of €87.8K at the end of 2025. Key ratios indicate solid capitalisation and efficient use of assets, including an equity ratio of 68.4%, debt-to-equity of 0.50 and asset turnover of 4.54x. Return on equity was 21.5% and return on assets 14.7%. Revenue per employee was €167.1K, while profit per employee was €5.4K.